Duke University Medical Center
Durham, North Carolina, 27710, United States
NCT Number: NCT04855305
The purpose of this multi-centered, NIH-sponsored study is to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Durham, North Carolina, 27710, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion/Exclusion Criteria for Healthy Volunteers
Inclusion criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
Exclusion criteria
Subjects presenting with any of the following will not be included in the trial:
Inclusion/Exclusion Criteria for Subjects with Interstitial Lung Disease
Inclusion criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the trial:
Exclusion criteria
Subjects presenting with any of the following will not be included in the trial:
Hyperpolarized 129Xe will be administered in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)
Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)
The RBC/Barrier Signal Ratio is a key quantitative metric in hyperpolarized Xe MRI that measures lung function by comparing the xenon signal in red blood cells (RBCs) to the signal in the pulmonary interstitial membrane (blood-gas barrier). It directly reflects how effectively xenon transfers across the membrane into the blood, with lower ratios indicating impairment in conditions like pulmonary fibrosis. For healthy individuals, this ratio is typically around a median (1Q-3Q) of 0.51 (0.45 - 0.57), while in subjects with pulmonary fibrosis, it can be significantly lower (e.g., 0.23 (0.21-0.24)).
Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)
A measure of how much maximum change in the RBC:Barrier is expected due to experimental variability. The coefficient of repeatability is calculated as 1.96 times the standard deviation observed in the RBC/barrier signal ratio.
Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)
Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)
The RBC/Barrier Signal Ratio is a key quantitative metric in hyperpolarized Xe MRI that measures lung function by comparing the xenon signal in red blood cells (RBCs) to the signal in the pulmonary interstitial membrane (blood-gas barrier). It directly reflects how effectively xenon transfers across the membrane into the blood, with lower ratios indicating impairment in conditions like pulmonary fibrosis. For healthy individuals, this ratio is typically around a median (1Q-3Q) of 0.51 (0.45 - 0.57), while in subjects with pulmonary fibrosis, it can be significantly lower (e.g., 0.23 (0.21-0.24)).
Bastiaan Driehuys
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07709260
Behavior, Interstitial Lung Diseases
Üsküdar, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02796781
Interstitial Lung Diseases, Lung Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT00129701
Apnea, Asthma
London, United Kingdom
View Trial DetailsNCT02763540
Disease, Interstitial Lung Diseases
Montpellier, France
View Trial Details